Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine PK and Safety in HIV-Infected Children and Adolescents
NCT03332095Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of doravirine in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jul 2018; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03332095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332095.